97 related articles for article (PubMed ID: 6510570)
1. Effect of low dosage of interferon on natural killer activity in patients with HBsAg-positive chronic active hepatitis.
Matsumura N; Yoshikawa T; Kondo M; Imanishi J; Kishida T
Digestion; 1984; 30(4):195-9. PubMed ID: 6510570
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of a low dosage of human leukocyte interferon on chronic hepatitis B virus infection.
Matsumura N; Yoshikawa T; Kondo M; Kawakami H; Kishida T
Digestion; 1983; 26(4):205-12. PubMed ID: 6873506
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg-positive chronic active hepatitis: results of a placebo vs. interferon trial.
Schalm SW; Heijtink RA
Hepatology; 1982; 2(6):791-4. PubMed ID: 7141389
[TBL] [Abstract][Full Text] [Related]
4. Recombinant leukocyte interferon treatment of chronic hepatitis B.
Dusheiko G; Dibisceglie A; Bowyer S; Sachs E; Ritchie M; Schoub B; Kew M
Hepatology; 1985; 5(4):556-60. PubMed ID: 4018728
[TBL] [Abstract][Full Text] [Related]
5. [Effect of interferon on hepatitis B virus infection in patients with chronic active hepatitis].
Hinoue Y; Unoura M; Kato Y; Kobayashi K; Hattori N
Gan To Kagaku Ryoho; 1984 Feb; 11(2):205-11. PubMed ID: 6696458
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of human leukocyte interferon on chronic active hepatitis B in children.
Hashida T; Sawada T; Esumi N; Kinugasa A; Kusunoki T; Kishida T
J Pediatr Gastroenterol Nutr; 1985 Feb; 4(1):20-5. PubMed ID: 3981364
[TBL] [Abstract][Full Text] [Related]
7. Transient increase of HBsAg levels following human IFN alpha treatment signalises the patient's response in chronic active hepatitis B.
Stancek D; Hajnická V; Blaskovicová H; Sudová J; Laktis K; Janota S; Jezek P
Acta Virol; 1990 Sep; 34(5):457-66. PubMed ID: 1981456
[TBL] [Abstract][Full Text] [Related]
8. Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers.
Actis GC; Maran E; Saracco G; Rosina F; Brunetto MR; Baldi M; Lattore V; Rocca G; Bonino F; Rizzetto M
Ric Clin Lab; 1987; 17(4):331-41. PubMed ID: 3438668
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
[TBL] [Abstract][Full Text] [Related]
10. The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.
Yoo YK; Gavaler JB; Chen K; Whiteside TL; van Thiel DH
Clin Exp Immunol; 1990 Nov; 82(2):338-43. PubMed ID: 2242614
[TBL] [Abstract][Full Text] [Related]
11. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.
Scullard GH; Smith CI; Merigan TC; Robinson WS; Gregory PB
Gastroenterology; 1981 Dec; 81(6):987-91. PubMed ID: 7286593
[TBL] [Abstract][Full Text] [Related]
12. Virus-associated receptors for polymerized human serum albumin (RpHSA) in patients with chronic active hepatitis B treated with recombinant leukocyte A interferon.
Gerken G; Manns M; Hess G; Meyer zum Büschenfelde KH
Digestion; 1987; 37(2):96-102. PubMed ID: 3040500
[TBL] [Abstract][Full Text] [Related]
13. Lymphoblastoid alpha-interferon weekly, daily and combined with acyclovir for chronic HBeAg-positive hepatitis.
Schalm SW; Heytink RA; Van Buuren HR; De Man RA
J Hepatol; 1986; 3 Suppl 2():S189-92. PubMed ID: 3598156
[TBL] [Abstract][Full Text] [Related]
14. Effects of human leucocyte interferon on hepatitis B virus replication and immune responses in patients with chronic hepatitis B infection.
Scullard GH; Alberti A; Wansbrough-Jones MH; Howard CR; Eddleston AL; Zuckerman AJ; Cantell K; Williams R
J Clin Lab Immunol; 1979 Feb; 1(4):277-82. PubMed ID: 501726
[TBL] [Abstract][Full Text] [Related]
15. Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B.
Kumada H; Ikeda K; Yoshida A; Seto S; Tsukada T; Kojima M; Suzuki H; Mayumi M
Jpn J Med; 1987 May; 26(2):217-22. PubMed ID: 3626161
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. A preliminary analysis of the first 32 patients.
Alexander GJ; Fagan EA; Guarner P; Rolando N; Brahm J; Eddleston AL; Williams R
J Hepatol; 1986; 3 Suppl 2():S183-8. PubMed ID: 3298406
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B.
Kagawa T; Morizane T; Saito H; Tsunematsu S; Tada S; Kumagai N; Tsuchimoto K; Sugiura H; Mukai M; Tsuchiya M
Am J Gastroenterol; 1993 Feb; 88(2):212-6. PubMed ID: 8424423
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B.
Tjwa ET; Zoutendijk R; van Oord GW; Biesta PJ; Verheij J; Janssen HL; Woltman AM; Boonstra A
Liver Int; 2014 Mar; 34(3):396-404. PubMed ID: 23890390
[TBL] [Abstract][Full Text] [Related]
20. Human lymphoblastoid and fibroblast interferon in the treatment of chronic hepatitis B.
Hayashi J; Noguchi A; Nakashima K; Hayashi S; Kashiwagi S; Mayumi T; Motomura M
Clin Ther; 1990; 12(1):12-21. PubMed ID: 2328524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
